Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results  show potential of RYBREVANT® beyond lung cancer BARCELONA , Sept. ...

Medical Technology has become a high-growth segment within the health care industry, while opening up new possibilities in patient care. On Bloomberg Chief Future Officer, Johnson & Johnson CFO Joe...

Between 2024 and 2030, the largest US pharma companies will lose patent protections on drugs that now account for $180 billion in sales. Johnson & Johnson has $15 billion in sales at risk of erosion.

Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management ...

The US nonfarm payrolls grew sharply on a month-over-month basis in August but still came in below the consensus forecast on Friday. The US economy added 142,000 jobs last month versus 89,000 in Ju...

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy Results from ...

Johnson & Johnson (NYSE:JNJ ) Wells Fargo 2024 Healthcare Conference September 5, 2024 11:00 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech Jessica ...

Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.

Johnson & Johnson is a remarkably consistent business. A fortress-like balance sheet all but guarantees the dividend's safety.

The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.

In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts.

If you are a Johnson & Johnson investor and have been enjoying the stock's steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on ki...

We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.

Johnson & Johnson (JNJ) closed the most recent trading day at $162.95, moving -1.01% from the previous trading session.

Investors have long sought to maximize gains by timing the market – buying low and selling high.